A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients

NCT02672540 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia, Sickle Cell

Interventions

DRUG: SANGUINATE 320 mg/kg
DRUG: Normal Saline

Sponsor

Prolong Pharmaceuticals